Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Argent Capital Management LLC

Argent Capital Management LLC cut its holdings in Edwards Lifesciences Co. (NYSE:EW) by 13.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,080 shares of the medical research company’s stock after selling 2,120 shares during the quarter. Argent Capital Management LLC’s holdings in Edwards Lifesciences were worth $1,042,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Roble Belko & Company Inc acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $46,000. Assenagon Asset Management S.A. grew its stake in Edwards Lifesciences by 475.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock valued at $314,182,000 after buying an additional 3,506,886 shares during the last quarter. Rockland Trust Co. grew its stake in Edwards Lifesciences by 8.3% in the 4th quarter. Rockland Trust Co. now owns 4,353 shares of the medical research company’s stock valued at $322,000 after buying an additional 334 shares during the last quarter. Fifth Third Wealth Advisors LLC grew its stake in Edwards Lifesciences by 5.2% in the 4th quarter. Fifth Third Wealth Advisors LLC now owns 5,584 shares of the medical research company’s stock valued at $413,000 after buying an additional 278 shares during the last quarter. Finally, Cullen Investment Group LTD. grew its stake in Edwards Lifesciences by 3.7% in the 4th quarter. Cullen Investment Group LTD. now owns 20,543 shares of the medical research company’s stock valued at $1,521,000 after buying an additional 739 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on EW shares. Daiwa America lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Robert W. Baird lowered their target price on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Citigroup increased their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Truist Financial reaffirmed a “hold” rating and set a $78.00 price objective (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Finally, Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $82.00 to $90.00 in a research note on Monday, December 16th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $78.48.

Edwards Lifesciences Trading Down 1.1 %

NYSE:EW opened at $70.29 on Thursday. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The company has a market cap of $41.46 billion, a PE ratio of 10.14, a PEG ratio of 3.77 and a beta of 1.11. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm has a 50-day moving average of $71.82 and a 200-day moving average of $71.62.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting the consensus estimate of $0.67. The firm had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.59 earnings per share. As a group, equities research analysts expect that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 2,500 shares of the stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $74.08, for a total value of $185,200.00. Following the completion of the sale, the vice president now owns 23,189 shares in the company, valued at $1,717,841.12. This represents a 9.73 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 32,500 shares of company stock worth $2,160,800. Corporate insiders own 1.27% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.